Business Context and Reporting Period
Celularity Inc. filed a Form 8-K dated June 20, 2023, reporting an amended and restated senior secured loan agreement with Resorts World Inc. Pte Ltd. The transaction closed on June 21, 2023. This filing does not report quarterly or annual operating results.
Key Financial and Capital Structure Terms
- Additional borrowing: $6.0 million aggregate principal amount, net of a $678,000 original issue discount.
- Interest rate: 12.5% annually; interest for the first year is payable in kind monthly.
- Maturity: March 17, 2025, including an extension of the maturity date of the initial RWI loan.
- Use of proceeds: Net proceeds must be applied to amounts due to YA II PN, Ltd. under a September 15, 2022 prepaid advance agreement. Other uses require RWI’s prior written approval.
- Warrants: RWI received warrants to purchase up to 3,000,000 shares of Class A common stock. The warrants have a five-year term and an exercise price of $0.81 per share. The stated warrant purchase price was $0.125 per underlying share, or $375,000 in total.
- Security: Celularity granted RWI a senior security interest in all assets, ranking pari passu with the security interest of C.V. Starr & Co., Inc. under its previously disclosed senior secured bridge loan.
Material Changes and Management Considerations
- The amended agreement increases available borrowing, restates the prior RWI loan, and extends its maturity to March 17, 2025.
- The financing carries a high 12.5% interest rate and includes payment-in-kind interest for the first year, which may increase the outstanding debt balance.
- Celularity is subject to customary negative covenants, including restrictions on dividends, repayment or incurrence of indebtedness, and liens, except as permitted under the agreement.
- Celularity must not hold cash and cash equivalents below $3 million for more than five consecutive business days.
- The agreement includes customary events of default.
- RWI is affiliated with Lim Kok Thay, a member of Celularity’s board of directors, making the financing a related-party transaction.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no revenue, profit, cash-flow, margin, liquidity balance, or operating guidance. Key risks include increased leverage, high interest expense, dilution from the warrants, restrictions on financial flexibility, pledged assets, minimum-cash requirements, and potential default consequences. The filing text does not provide a clear value for Celularity’s cash balance or total debt after the transaction.
Investor Verification Checklist
- Review the full amended and restated loan agreement filed as Exhibit 10.1, including repayment terms, covenants, collateral, and events of default.
- Verify the final amount funded, treatment of the $678,000 original issue discount, and the amount applied to the Yorkville obligation.
- Confirm the outstanding principal and accrued payment-in-kind interest in subsequent filings.
- Assess potential dilution from the 3,000,000 RWI warrants and the related-party nature of the transaction.
- Review Celularity’s subsequent financial statements for cash levels, liquidity, debt maturities, and covenant compliance.